Drug choices in autoimmune hepatitis: Part A - Steroids

Expert Review of Gastroenterology and Hepatology

Volumn 6, Issue 5, 2012, Pages 603-615

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

autoimmune hepatitis; budesonide; pharmacokinetics; prednisolone; prednisone; preferences; therapeutic actions; treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BARBITURIC ACID DERIVATIVE; BUDESONIDE; CARBAMAZEPINE; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CXCR2; CLARITHROMYCIN; COLLAGEN; CORTICOSTEROID; CXCL1 CHEMOKINE; CYTOCHROME P450 3A4; GENERIC DRUG; GLUCOCORTICOID RECEPTOR; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; KETOCONAZOLE; PHENYTOIN; PREDNISOLONE; PREDNISONE; RIFAMPICIN;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AUTOIMMUNE HEPATITIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE GENE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FOOD DRUG INTERACTION; GENE; GENE EXPRESSION; GLUCOSE INTOLERANCE; GRAPEFRUIT JUICE; HUMAN; HYPERTENSION; INDIVIDUALIZATION; INHIBITION KINETICS; LYMPHOCYTE ACTIVATION; MAXIMUM PLASMA CONCENTRATION; MENTAL INSTABILITY; OSTEOPENIA; PANCREATITIS; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

BUDESONIDE; GLUCOCORTICOIDS; HEPATITIS, AUTOIMMUNE; HUMANS; PREDNISOLONE; PREDNISONE;

EID: 84867492451     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.12.40     Document Type: Review

References (99)

1. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q. J. Med. 40(158), 159-185 (1971).
2. Soloway RD, Summerskill WH, Baggenstoss AH et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 63(5), 820-833 (1972).
3. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1(7806), 735-737 (1973).
4. Manns MP, Czaja AJ, Gorham JD et al. American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology 51(6), 2193-2213 (2010).
5. Strassburg CP, Manns MP. Therapy of autoimmune hepatitis. Best Pract. Res. Clin. Gastroenterol. 25(6), 673-687 (2011).
6. Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin. Drug Saf. 7(3), 319-333 (2008). (Pubitemid 351802831)
7. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: Role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am. J. Gastroenterol. 99(8), 1510-1516 (2004). (Pubitemid 39180099)
8. Miyake Y, Iwasaki Y, Terada R et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J. Hepatol. 43(6), 951-957 (2005). (Pubitemid 41627979)
9. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am. J. Gastroenterol. 102(5), 1005-1012 (2007). (Pubitemid 46698236)
10. Wörns MA, Teufel A, Kanzler S et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am. J. Gastroenterol. 103(1), 138-146 (2008).
11. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 139(1), 58-72.e4 (2010).
12. Czaja AJ. Advances in the Current Treatment of Autoimmune Hepatitis. Dig. Dis. Sci.57(8), 1996-2010 (2012).
13. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: A retrospective analysis. Hepatology 35(4), 890-897 (2002). (Pubitemid 34258384)
14. Czaja AJ. Recurrent autoimmune hepatitis after liver transplantation. Ann. Gastroenterol. Hepatol. 1, 79-89 (2010).
15. Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 95(2), 448-453 (1988).
16. Kanzler S, Löhr H, Gerken G, Galle PR, Lohse AW. Long-term management and prognosis of autoimmune hepatitis (AIH): A single center experience. Z. Gastroenterol. 39(5), 339-41, 344 (2001).
17. Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J. Hepatol. 51(1), 161-167 (2009).
18. Czaja AJ. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transpl. 8(6), 505-513 (2002). (Pubitemid 34619081)
19. Czaja AJ. Diagnosis, Pathogenesis, and Treatment of Autoimmune Hepatitis After Liver Transplantation. Dig. Dis. Sci. 57(9), 2248-2266 (2012).
20. Neuberger J. Transplantation for autoimmune hepatitis. Semin. Liver Dis. 22(4), 379-386 (2002).
21. Khalaf H, Mourad W, El-Sheikh Y et al. Liver transplantation for autoimmune hepatitis: A single-center experience. Transplant. Proc. 39(4), 1166-1170 (2007). (Pubitemid 46764831)
22. Hayashi M, Keeffe EB, Krams SM et al. Allograft rejection after liver transplantation for autoimmune liver diseases. Liver Transpl. Surg. 4(3), 208-214 (1998). (Pubitemid 28225647)
23. Vogel A, Heinrich E, Bahr MJ et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin. Transplant. 18(1), 62-69 (2004). (Pubitemid 38195546)
24. Trouillot TE, Shrestha R, Kam I, Wachs M, Everson GT. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis. Liver Transpl. Surg. 5(5), 375-380 (1999). (Pubitemid 29437014)
25. Campsen J, Zimmerman MA, Trotter JF et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl. 14(9), 1281-1286 (2008).
26. Lohse AW, Weiler-Norman C, Burdelski M. De novo autoimmune hepatitis after liver transplantation. Hepatol. Res. 37(Suppl. 3), S462 (2007).
27. Liberal R, Longhi MS, Grant CR, Mieli-Vergani G, Vergani D. Autoimmune hepatitis after liver transplantation. Clin. Gastroenterol. Hepatol. 10(4), 346-353 (2012).
28. Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: Dose titration, standard dose, and combination with azathioprine compared. Gut 16(11), 876-883 (1975).
29. Czaja AJ. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr. Pharm. Des. 17(29), 3120-3140 (2011).
30. Czaja AJ. Current and future treatments of autoimmune hepatitis. Expert Rev. Gastroenterol. Hepatol. 3(3), 269-291 (2009).
31. Czaja AJ. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig. Dis. Sci. 55(10), 2712-2726 (2010).
32. Czaja AJ. Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis. Part-I. Inflamm. Allergy Drug Targets PMID: 22563779 (2012)(Epub ahead of print).
33. Czaja AJ. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part-II. Inflamm. Allergy Drug Targets PMID: 22563780 (2012) (Epub ahead of print).and genetic (gene silencing and gene transfer) interventions for autoimmune hepatitis.
34. Czaja AJ. Autoimmune hepatitis: Focusing on treatments other than steroids. Can. J. Gastroenterol. (2012) (In Press).
35. Czaja AJ, Bianchi FB, Carpenter HA et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 41(1), 207-215 (2005). (Pubitemid 40066400)
36. Manns MP. Autoimmune hepatitis: The dilemma of rare diseases. Gastroenterology 140(7), 1874-1876 (2011).
37. Schalm SW, Summerskill WH, Go VL. Development of radioimmunoassays for prednisone and prednisolone. Application to studies of hepatic metabolism of prednisone. Mayo Clin. Proc. 51(12), 761-766 (1976). (Pubitemid 8014860)
38. Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin. Pharmacokinet. 44(1), 61-98 (2005). (Pubitemid 40096038)
39. Schalm SW, Summerskill WH, Go VL. Prednisone for chronic active liver disease: Pharmacokinetics, including conversion to prednisolone. Gastroenterology 72(5 Pt 1), 910-913 (1977). (Pubitemid 8093903)
40. Uribe M, Schalm SW, Summerskill WH, Go VL. Oral prednisone for chronic active liver disease: Dose responses and bioavailability studies. Gut 19(12), 1131-1135 (1978). (Pubitemid 9108631)
41. Uribe M, Go VL. Corticosteroid pharmacokinetics in liver disease. Clin. Pharmacokinet. 4(3), 233-240 (1979).
42. Uribe M, Summerskill WH, Go VL. Comparative serum prednisone and prednisolone concentrations following administration to patients with chronic active liver disease. Clin. Pharmacokinet. 7(5), 452-459 (1982). (Pubitemid 12057032)
43. Uribe M, Go VL, Kluge D. Prednisone for chronic active hepatitis: Pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side effects. J. Clin. Gastroenterol. 6(4), 331-335 (1984). (Pubitemid 14053703)
44. Diederich S, Hanke B, Burkhardt P et al. Metabolism of synthetic corticosteroids by 11 β-hydroxysteroid-dehydrogenases in man. Steroids 63(5-6), 271-277 (1998). (Pubitemid 28265659)
45. Diederich S, Eigendorff E, Burkhardt P et al. 11-β-hydroxysteroid dehydrogenase types 1 and 2: An important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J. Clin. Endocrinol. Metab. 87(12), 5695-5701 (2002). (Pubitemid 36034378)
46. Maser E, Völker B, Friebertshäuser J. 11 β-hydroxysteroid dehydrogenase type 1 from human liver: Dimerization and enzyme cooperativity support its postulated role as glucocorticoid reductase. Biochemistry 41(7), 2459-2465 (2002). (Pubitemid 34160910)
47. Brattsand R, Linden M. Cytokine modulation by glucocorticoids: Mechanisms and actions in cellular studies. Aliment. Pharmacol. Ther. 10(Suppl. 2), 81-90; discussion 91 (1996). (Pubitemid 26341300)
48. De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: Negative interference of activated glucocorticoid receptor with transcription factors. J. Neuroimmunol. 109(1), 16-22 (2000).
49. Almawi WY. Molecular mechanisms of glucocorticoid effects. Mod. Asp. Immunobiol., 2, 78-82 (2001).
50. Czaja AJ. Autoimmune hepatitis. Part A: Pathogenesis. Expert Rev. Gastroenterol. Hepatol. 1(1), 113-128 (2007).
51. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am. J. Gastroenterol. 96(4), 1224-1231 (2001). (Pubitemid 32319165)
52. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J. Hepatol. 40(4), 646-652 (2004). (Pubitemid 38367787)
53. Almawi WY, Beyhum HN, Rahme AA, Rieder MJ. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J. Leukoc. Biol. 60(5), 563-572 (1996). (Pubitemid 26400412)
54. Migita K, Eguchi K, Kawabe Y et al. Apoptosis induction in human peripheral blood T lymphocytes by high-dose steroid therapy. Transplantation 63(4), 583-587 (1997). (Pubitemid 27102629)
55. Leussink VI, Jung S, Merschdorf U, Toyka KV, Gold R. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch. Neurol. 58(1), 91-97 (2001). (Pubitemid 32053212)
56. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 275(4), 2247-2250 (2000). (Pubitemid 30081976)
57. Murphy FR, Issa R, Zhou X et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: Implications for reversibility of liver fibrosis. J. Biol. Chem. 277(13), 11069-11076 (2002). (Pubitemid 34952866)
58. Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 39(6), 1631-1638 (2004). (Pubitemid 38702664)
59. Lewis GP, Jusko WJ, Graves L, Burke CW. Prednisone side-effects and serum-protein levels. A collaborative study. Lancet 2(7728), 778-780 (1971).
60. Centeno F, Robles G, Uribe M, Lozada SG, Suárez GI. Nomogram for prednisone-prednisolone adjustment dose in patients with hypoalbuminemia. Rev. Invest. Clin. 30(1), 35-39 (1978).
61. Garg V, Jusko WJ. Bioavailability and reversible metabolism of prednisone and prednisolone in man. Biopharm. Drug Dispos. 15(2), 163-172 (1994). (Pubitemid 24089062)
62. Yates CR, Chang C, Kearbey JD et al. Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm. Res. 20(11), 1794-1803 (2003). (Pubitemid 37449453)
63. Ost L. Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. Transplantation 44(4), 533-535 (1987). (Pubitemid 17154153)
64. Clissold SP, Heel RC. Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 28(6), 485-518 (1984). (Pubitemid 15211796)
65. Mittmann N, Hernandez P, Mellström C, Brannman L, Welte T. Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives. Pharmacoeconomics 29(5), 403-414 (2011).
66. Silverman J, Otley A. Budesonide in the treatment of inflammatory bowel disease. Expert Rev. Clin. Immunol. 7(4), 419-428 (2011).
67. Stewart MJ, Seow CH, Storr MA. Prednisolone and budesonide for short- and long-term treatment of microscopic colitis: Systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 9(10), 881-890 (2011).
68. Straumann A, Conus S, Degen L et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin. Gastroenterol. Hepatol. 9(5), 400-409.e1 (2011).
69. Wiegand J, Schüler A, Kanzler S et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int. 25(5), 927-934 (2005). (Pubitemid 41404011)
70. Csepregi A, Röcken C, Treiber G, Malfertheiner P. Budesonide induces complete remission in autoimmune hepatitis. World J. Gastroenterol. 12(9), 1362-1366 (2006).
71. Manns MP, Bahr MJ, Woynarowski M et al. Budesonide 3 mg TID is superior to prednisolone in combination with azathioprine in the treatment of autoimmune hepatitis. J. Hepatol. 48 (Suppl. 2), Abstract S369 (2008).
72. Zandieh I, Krygier D, Wong V et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can. J. Gastroenterol. 22(4), 388-392 (2008). (Pubitemid 351772333)
73. Manns MP, Woynarowski M, Kreisel W et al.; European AIH-BUC-Study Group. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 139(4), 1198-1206 (2010).
74. Snider KR, Potter TG. Budesonide for the treatment of autoimmune hepatitis. Ann. Pharmacother. 45(9), 1144-1150 (2011).
75. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment. Pharmacol. Ther. 8(6), 585-590 (1994). (Pubitemid 24381357)
76. Geier A, Gartung C, Dietrich CG, Wasmuth HE, Reinartz P, Matern S. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: Influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J. Gastroenterol. 9(12), 2681-2685 (2003). (Pubitemid 38054439)
77. Efe C, Ozaslan E, Kav T et al. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmun. Rev. 11(5), 330-334 (2012).
78. McKay DM, Brattsand R, Wieslander E, Fung M, Croitoru K, Perdue MH. Budesonide inhibits T cell-initiated epithelial pathophysiology in an in vitro model of inflammation. J. Pharmacol. Exp. Ther. 277(1), 403-410 (1996). (Pubitemid 27169086)
79. Strandberg K, Blidberg K, Sahlander K, Palmberg L, Larsson K. Effect of formoterol and budesonide on chemokine release, chemokine receptor expression and chemotaxis in human neutrophils. Pulm. Pharmacol. Ther. 23(4), 316-323 (2010).
80. Longui CA, Santos MC, Formiga CB et al. Antiproliferative and apoptotic potencies of glucocorticoids: Nonconcordance with their antiinflammatory and immunosuppressive properties. Arq. Bras. Endocrinol. Metabol. 49(3), 378-383 (2005).
81. von Scheele I, Larsson K, Palmberg L. Budesonide enhances Toll-like receptor 2 expression in activated bronchial epithelial cells. Inhal. Toxicol. 22(6), 493-499 (2010).
82. Hofkens W, van den Hoven JM, Pesman GJ et al. Safety of glucocorticoids can be improved by lower yet still effective dosages of liposomal steroid formulations in murine antigen-induced arthritis: Comparison of prednisolone with budesonide. Int. J. Pharm. 416(2), 493-498 (2011).
83. Ryrfeldt A, Andersson P, Edsbäcker S, Tönnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur. J. Respir. Dis. Suppl. 122, 86-95 (1982). (Pubitemid 13235843)
84. Dilger K, Alberer M, Busch A et al. Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease. Aliment. Pharmacol. Ther. 23(3), 387-396 (2006). (Pubitemid 43382019)
85. Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin. Pharmacokinet. 40(10), 723-751 (2001). (Pubitemid 33027888)
86. Edsbäcker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin. Pharmacokinet. 43(12), 803-821 (2004). (Pubitemid 39382221)
87. Jönsson G, Aström A, Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab. Dispos. 23(1), 137-142 (1995).
88. Dilger K, Schwab M, Fromm MF. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm. Bowel Dis. 10(5), 578-583 (2004). (Pubitemid 39276465)
89. Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 38(1), 196-202 (2003). (Pubitemid 36775811)
90. Mederacke I, Helfritz F, Puls F et al. Budd-Chiari syndrome after treatment with budesonide in a cirrhotic patient with autoimmune hepatitis. Ann. Hepatol. 11(1), 143-144 (2012).
91. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatmentdependent autoimmune hepatitis. Gastroenterology 119(5), 1312-1316 (2000).
92. Lohse AW, Gil H. Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment. J. Hepatol. 54(4), 837-839 (2011).
93. Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int. 29(6), 816-823 (2009).
94. Czaja AJ. Autoimmune hepatitis in special patient populations. Best Pract. Res. Clin. Gastroenterol. 25(6), 689-700 (2011).
95. Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis J. Hepatol. 31(5), 929-938 (1999). (Pubitemid 29514229)
96. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 46(4), 1138-1145 (2007). (Pubitemid 350144778)
97. Yeoman AD, Westbrook RH, Zen Y et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology 53(3), 926-934 (2011).
98. Czaja AJ. Treatment strategies in autoimmune hepatitis. Clin. Liver Dis. 6(3), 799-824 (2002).
99. Czaja AJ. Animal models of autoimmune hepatitis. Expert Rev. Gastroentero